26-04-2025
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and VYNE Therapeutics (VYNE)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Roche Holding AG (RHHVF – Research Report) and VYNE Therapeutics (VYNE – Research Report) with bullish sentiments.
Stay Ahead of the Market:
Discover outperforming stocks and invest smarter with Top Smart Score Stocks.
Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener.
Roche Holding AG (RHHVF)
Kepler Capital analyst David Evans maintained a Buy rating on Roche Holding AG on April 24 and set a price target of CHF315.00. The company's shares closed last Friday at $318.07.
Evans has an average return of 10.6% when recommending Roche Holding AG.
According to Evans is ranked #6071 out of 9437 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Roche Holding AG with a $351.87 average price target, representing a 12.6% upside. In a report issued on April 16, Exane BNP Paribas also initiated coverage with a Buy rating on the stock with a CHF300.00 price target.
LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on VYNE Therapeutics yesterday and set a price target of $6.00. The company's shares closed last Friday at $1.43.
According to Katkhuda is a 5-star analyst with an average return of 14.5% and a 35.4% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., MoonLake Immunotherapeutics, and Eledon Pharmaceuticals.
VYNE Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $6.19, a 324.0% upside from current levels. In a report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $4.50 price target.
